Danielle Raufaste

Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes

P. Casellas, J. Maffrand, M. Lafontan, 2000, FEBS letters.

Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.

P. Rochard, C. Serradeil-Le Gal, M. Pascal, 2003, American journal of physiology. Endocrinology and metabolism.

Binding of the Non-Peptide Vasopressin V1a Receptor Antagonist SR-49059 in the Rat Brain: An in vitro and in vivo Autoradiographic Study

E. Tribollet, J. Maffrand, C. Serradeil-Le Gal, 1999, Neuroendocrinology.

Single Amino Acid Substitutions and Deletions That Alter the G Protein Coupling Properties of the V2 Vasopressin Receptor Identified in Yeast by Receptor Random Mutagenesis*

C. S. Gal, J. Wess, E. Kostenis, 2001, The Journal of Biological Chemistry.

SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor

B. Scatton, J. Maffrand, E. Naline, 2004, Journal of Pharmacology and Experimental Therapeutics.

PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice.

S. Nielsen, J. Verbavatz, O. Devuyst, 2007, Journal of the American Society of Nephrology : JASN.

Endothelin action in rat liver. Receptors, free Ca2+ oscillations, and activation of glycogenolysis.

P. Cobbold, J. Hanoune, S. Lotersztajn, 1991, The Journal of clinical investigation.

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

C. S. Gal, G. Fur, L. Bankir, 1996, The Journal of clinical investigation.